“This is exciting, because it has clinical impact,” said Alexandra Straus, Ph.D., a postdoctoral fellow in the VCU Department of Cellular, Molecular and Genetic Medicine, who is also a collaborator on the paper. “As scientists that are at the bench, it’s important to think about how a clinical trial might be working, and these findings can help us identify potential biomarkers for understanding which patients might benefit most.”
What are the main findings of this research?
Researchers in the lab of Can Senkal, Ph.D., interim director of the Lipidomics and Metabolomics Shared Resource and member of the Cancer Biology research program at Massey, treated cancer cell lines that represent primary focuses in Massey’s catchment area—colon, ovarian and cervical cells—with eliglustat, a known inhibitor of GCS.